Month: August 2021

2024.07.17
Summary of the most important events and achievements of the Genomtec S.A.

2024.06.25
Webinar: Trends in the M&A Market Specific to In-Vitro Diagnostics | 27 June, 2024, 3:00 p.m. (CEST)

2024.04.22
Dr. Trevor Hawkins, a distinguished entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Genomtec S.A.

2024.03.26
Genomtec secures PLN 10.6 million to fund scientific research and development of the oncology project - Company will raise capital from founding shareholders and investors

2024.03.26
Genomtec strengthens the Supervisory Board with individuals who bring extensive industry and business experience

Archive

2021.08.25

Genomtec has filed a patent application for a set of primers for detecting Salmonella enterica infections, one of the most common infectious diseases among humans and animals

Company has filed a patent application for a proprietary primer set, diagnostic method and reaction mixture composition for genetic diagnosis of ...
Read
2021.08.16

Genomtec intends to move to the Main Market of the Warsaw Stock Exchange (WSE)

Genomtec S.A. has expressed its intention to seek a transfer of the Company’s listing from the alternative stock exchange of NewConnect to ...
Read
2021.08.12

Genomtec’s flagship solution enters critical development phase. Company summarizes second quarter activities

Genomtec S.A. has published a report for the second quarter of 2021 containing financial results and a summary of the most important activities ...
Read
2021.08.06

Genomtec receives ISO 13485 certification completing another essential step in the Genomtec ID project

Genomtec SA has been certified in accordance to ISO 13485 standard for its quality management system compliance via audits carried out by TÜV ...
Read

Archive